Preclinical data showed that erdafitinib has the potential to induce a prolonged inhibition of FGFR signalling, which is accompanied by reduced proliferation in a range of human lung cancer cell lines with FGFR1 amplifications [111]. The gene discussed is FGFR1; the disease is lung carcinoma.